


WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure:



wherein:

----- is a single bond or double bond;

R¹ is selected from the group consisting of hydrogen, an unsubstituted C₁₋₄ alkyl, -C(=O)Y¹, -C(=O)-O-Y¹, -(CH₂)₂-O-(C=O)-Y¹, -(CH₂)₂-O-(C=O)-O-Y¹, -(CHCH₃)-O-(C=O)-Y¹ and -(CHCH₃)-O-(C=O)-O-Y¹;

R² is selected from the group consisting of hydrogen, an optionally substituted C₁₋₆ alkyl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C₁₋₆ alkyl), an optionally substituted aryl(C₁₋₆ alkyl), an optionally substituted heteroaryl(C₁₋₆ alkyl) and an optionally substituted heterocyclyl(C₁₋₆ alkyl);

R³ᵃ and R³ᵇ are independently hydrogen or an optionally substituted C₁₋₄ alkyl;

R⁴ and R⁵ are independently selected from the group consisting of hydrogen, an optionally substituted aryl, an optionally substituted aryl(C₁₋₆ alkyl), an optionally substituted heteroaryl and an optionally substituted heteroaryl(C₁₋₆ alkyl), provided that at least one of R⁴ and R⁵ is not hydrogen; or

R⁴ and R⁵ are taken together to form an optionally substituted tricyclic cycloalkenyl or an optionally substituted tricyclic heterocyclyl;


R⁶ is selected from the group consisting of hydrogen, halogen, -CN, an optionally substituted C₁₋₆ alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, -CH₂OH, -CH(Y²)(OH) and -C(O)Y²;

Y^1 and Y^2 are independently selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, a mono-substituted amino group, a di-substituted amino and $-C(R^7)NHR^8$; and


R^7 and R^8 are independently hydrogen or an optionally substituted C_{1-4} alkyl.

2. The compound of Claim 1, wherein R^4 is hydrogen.
3. The compound of Claim 1, wherein R^4 is an optionally substituted aryl.
4. The compound of Claim 3, wherein the optionally substituted aryl is an optionally substituted phenyl.
5. The compound of Claim 1, wherein R^4 is an optionally substituted aryl(C_{1-6} alkyl).
6. The compound of Claim 1, wherein R^4 is an optionally substituted heteroaryl.
7. The compound of Claim 6, wherein the optionally substituted heteroaryl is an optionally substituted imidazole or an optionally substituted pyrazole.
8. The compound of Claim 1, wherein R^4 is an optionally substituted heteroaryl(C_{1-6} alkyl).
9. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted aryl.
10. The compound of Claim 9, wherein the optionally substituted aryl is an optionally substituted phenyl.
11. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted aryl(C_{1-6} alkyl).
12. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted heteroaryl.
13. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted heteroaryl(C_{1-6} alkyl).
14. The compound of Claim 1, wherein R^4 and R^5 are each a substituted phenyl substituted with one or more group selected from fluoro, chloro, iodo, C_{1-4} alkyl, C_{2-4} alkynyl, hydroxy, C_{1-4} alkoxy, an optionally substituted phenyl, cyano, $NC-(CH_2)-$, $H_2N-C(=O)-$

(CH₂)-, O-amido(CH₂)-, optionally substituted




and optionally substituted



15. The compound of Claim 1, wherein R⁴ and R⁵ are taken together to form an optionally substituted tricyclic heterocyclyl.

16. The compound of Claim 15, wherein the optionally substituted tricyclic heterocyclyl is an optionally substituted moiety selected from the group consisting of:



and

17. The compound of Claim 15 or 16, wherein the tricyclic heterocyclyl is substituted with one or more group selected from fluoro, chloro, iodo and C₁₋₄ alkyl.

18. The compound of any one of Claims 1-17, wherein R² is hydrogen.

19. The compound of any one of Claims 1-17, wherein R² is an optionally substituted C₁₋₆ alkyl.

20. The compound of Claim 19, wherein the optionally substituted C₁₋₆ alkyl is substituted with substituent selected from the group consisting of halogen, haloalkyl, hydroxy and alkoxy.

21. The compound of any one of Claims 1-17, wherein R² is an optionally substituted aryl(C₁₋₆ alkyl).

22. The compound of any one of Claims 1-21, wherein R¹ is hydrogen.

23. The compound of any one of Claims 1-21, wherein R¹ is an unsubstituted C₁₋₄ alkyl.

24. The compound of any one of Claims 1-21, wherein R^1 is $-C(=O)Y^1$, $-C(=O)-O-Y^1$, $-(CH_2)-O-(C=O)-Y^1$, $-(CH_2)-O-(C=O)-O-Y^1$, $-(CHCH_3)-O-(C=O)-Y^1$ or $-(CHCH_3)-O-(C=O)-O-Y^1$.

25. The compound of Claim 24, R^1 is $-C(=O)Y^1$.

26. The compound of Claim 24, R^1 is $-C(=O)-O-Y^1$.

27. The compound of Claim 24, R^1 is $-(CH_2)-O-(C=O)-Y^1$.

28. The compound of Claim 24, R^1 is $-(CH_2)-O-(C=O)-O-Y^1$.

29. The compound of Claim 24, R^1 is $-(CHCH_3)-O-(C=O)-Y^1$.

30. The compound of Claim 24, R^1 is $-(CHCH_3)-O-(C=O)-O-Y^1$.

31. The compound of any one of Claims 24-30, Y^1 is an optionally substituted C_{1-6} alkyl.

32. The compound of any one of Claims 24-30, Y^1 is an optionally substituted C_{3-6} cycloalkyl.

33. The compound of any one of Claims 24-30, Y^1 is an optionally substituted aryl.

34. The compound of any one of Claims 24-30, Y^1 is an optionally substituted heteroaryl.

35. The compound of any one of Claims 24-30, Y^1 is an optionally substituted heterocyclyl.

36. The compound of any one of Claims 24-30, Y^1 is a mono-substituted amino group.

37. The compound of any one of Claims 24-30, Y^1 is a di-substituted amino

38. The compound of any one of Claims 24-30, Y^1 is $-C(R^7)NHR^8$.


39. The compound of Claim 38, wherein R^7 is hydrogen.

40. The compound of Claim 38, wherein R^7 is an optionally substituted C_{1-4} alkyl.

41. The compound of any one of Claims 38-40, wherein R^8 is hydrogen.

42. The compound of any one of Claims 38-40, wherein R^8 is an optionally substituted C_{1-4} alkyl.

43. The compound of Claim 38, wherein $-C(R^7)NHR^8$ is selected from



, wherein Het can be an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

44. The compound of any one of Claims 1-43, wherein R^6 is hydrogen.

45. The compound of any one of Claims 1-43, wherein R^6 is halogen or $-CN$.

46. The compound of any one of Claims 1-43, wherein R^6 is an optionally substituted C_{1-6} alkyl, an optionally substituted aryl or an optionally substituted heteroaryl.

47. The compound of any one of Claims 1-43, wherein R^6 is $-CH_2OH$, $-CH(Y^2)(OH)$ or $-C(O)Y^2$.

48. The compound of any one of Claims 1-47, wherein R^{3a} is hydrogen.

49. The compound of any one of Claims 1-47, wherein R^{3a} is an optionally substituted C_{1-4} alkyl.


50. The compound of any one of Claims 1-49, wherein R^{3b} is hydrogen.


51. The compound of any one of Claims 1-49, wherein R^{3b} is an optionally substituted C_{1-4} alkyl.














52. The compound of any one of Claims 1-51, wherein ----- is a single bond.













53. The compound of any one of Claims 1-51, wherein ----- is a double bond.











54. The compound of Claim 1, wherein the compound is selected from the group consisting of:











































55. The compound of Claim 1, wherein the compound is selected from the group consisting of:















and


, or a pharmaceutically acceptable salt

of the foregoing.


56. The compound of Claim 1, wherein the compound is selected from the group consisting of:







57. The compound of Claim 1, wherein the compound is selected from the group consisting of:



58. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

59. A method for ameliorating or treating an orthomyxovirus infection comprising administering an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58.

60. A method for inhibiting replication of an orthomyxovirus virus comprising contacting a cell infected with the virus with an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58.

61. A method for contacting a cell infected with an orthomyxovirus virus comprising contacting a cell infected with the virus with an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58.

62. A method for ameliorating or treating an orthomyxovirus infection in combination with one or more agents comprising administering or contacting a cell with an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58.

63. A method for inhibiting endonuclease activity of an influenza endonuclease comprising contacting the active site of the endonuclease with an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58.

64. The method of any one of Claims 59-61, wherein the orthomyxovirus viral infection is influenza.

65. The method of Claim 62, wherein the orthomyxovirus viral infection is an influenza virus infection; and wherein the one or more agents is selected from the group consisting of a neuraminidase inhibitor, a M2 protein inhibitor, a polymerase inhibitor, a PB2 inhibitor, amantadine, rimantadine, zanamivir, oseltamivir, peramivir, laninamivir, laninamivir octanoate, favipiravir, fludase, ADS-8902, an immuno-modulator, beraprost, Neugene®, ribavirin, CAS Reg. No. 1422050-75-6, CAS Reg. No. 1259366-34-1 (VX-787), FluMist Quadrivalent® (MedImmune), Fluarix® Quadrivalent (GlaxoSmithKline), Fluzone® Quadrivalent (Sanofi Pasteur), Flucelvax® (Novartis) and FluBlok® (Protein Sciences).

66. The method of 65, wherein the one or more agents is oseltamivir.

67. The method of any one of Claims 64-66, wherein the influenza is influenza A.

68. The method of any one of Claims 64-66, wherein the influenza is influenza B.

69. The method of any one of Claims 64-66, wherein the influenza is influenza C.

70. The method of any one of Claims 64-66, wherein the influenza is selected from the group consisting of H1N1, H3N2, H5N1 and H7N9.

71. The method of any one of Claims 59-70, wherein the compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 58 is effective against more than 1 subtype of influenza.

72. Use of an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58 in the preparation of a medicament for ameliorating or treating an orthomyxovirus viral infection.

73. Use of an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58 in the preparation of a medicament for inhibiting replication of an orthomyxovirus virus.

74. Use of an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58 in the preparation of a medicament for contacting a cell infected with an orthomyxovirus virus.

75. Use of an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58 in the preparation of a medicament for ameliorating or treating an orthomyxovirus viral infection in combination with one or more agents comprising administering or contacting a cell with an effective amount of the compound, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

76. Use of an effective amount of a compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 58 in the preparation of a medicament for inhibiting endonuclease activity of an influenza endonuclease.

77. The use of any one of Claims 72-74, wherein the orthomyxovirus viral infection is influenza.


78. The use of Claim 75, wherein the orthomyxovirus viral infection is an influenza virus infection; and wherein the one or more agents is selected from the group consisting of a neuraminidase inhibitor, a M2 protein inhibitor, a polymerase inhibitor, a PB2

inhibitor, amantadine, rimantadine, zanamivir, oseltamivir, peramivir, laninamivir, laninamivir octanoate, favipiravir, fludase, ADS-8902, an immuno-modulator, beraprost, Neugene®, ribavirin, CAS Reg. No. 1422050-75-6, CAS Reg. No. 1259366-34-1 (VX-787), FluMist Quadrivalent® (MedImmune), Fluarix® Quadrivalent (GlaxoSmithKline), Fluzone® Quadrivalent (Sanofi Pasteur), Flucelvax® (Novartis) and FluBlok® (Protein Sciences).

79. The use of 78, wherein the one or more agents is oseltamivir.
80. The use of any one of Claims 77-79, wherein the influenza is influenza A.
81. The use of any one of Claims 77-79, wherein the influenza is influenza B.
82. The use of any one of Claims 77-79, wherein the influenza is influenza C.
83. The use of any one of Claims 77-79, wherein the influenza is selected from the group consisting of H1N1, H3N2, H5N1 and H7N9.
84. The use of any one of Claims 72-83, wherein the compound of any one of Claims 1-57, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 58 is effective against more than 1 subtype of influenza.

CLAIMS

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure:



wherein:

----- is a single bond or double bond;

R¹ is selected from the group consisting of hydrogen, an unsubstituted C₁₋₄ alkyl, -C(=O)Y¹, -C(=O)-O-Y¹, -(CH₂)-O-(C=O)-Y¹, -(CH₂)-O-(C=O)-O-Y¹, -(CHCH₃)-O-(C=O)-Y¹ and -(CHCH₃)-O-(C=O)-O-Y¹;

R² is selected from the group consisting of hydrogen, an optionally substituted C₁₋₆ alkyl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C₁₋₆ alkyl), an optionally substituted aryl(C₁₋₆ alkyl), an optionally substituted heteroaryl(C₁₋₆ alkyl) and an optionally substituted heterocyclyl(C₁₋₆ alkyl);

R³ᵃ and R³ᵇ are independently hydrogen or an optionally substituted C₁₋₄ alkyl;

R⁴ and R⁵ are independently selected from the group consisting of hydrogen, an optionally substituted aryl, an optionally substituted aryl(C₁₋₆ alkyl), an optionally substituted heteroaryl and an optionally substituted heteroaryl(C₁₋₆ alkyl), provided that at least one of R⁴ and R⁵ is not hydrogen; or

R⁴ and R⁵ are taken together to form an optionally substituted tricyclic cycloalkenyl or an optionally substituted tricyclic heterocyclyl;

R⁶ is selected from the group consisting of hydrogen, halogen, -CN, an optionally substituted C₁₋₆ alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, -CH₂OH, -CH(Y²)(OH) and -C(O)Y²;



Y¹ and Y² are independently selected from the group consisting of an optionally substituted C₁₋₆ alkyl, an optionally substituted C₃₋₆ cycloalkyl, an optionally substituted aryl, an

optionally substituted heteroaryl, an optionally substituted heterocyclyl, a mono-substituted amino group, a di-substituted amino group and $-C(R^7)NHR^8$; and

R^7 and R^8 are independently hydrogen or an optionally substituted C_{1-4} alkyl.

2. The compound of Claim 1, wherein R^4 is hydrogen.
3. The compound of Claim 1, wherein R^4 is an optionally substituted aryl.
4. The compound of Claim 3, wherein the optionally substituted aryl is an optionally substituted phenyl.
5. The compound of Claim 1, wherein R^4 is an optionally substituted aryl(C_{1-6} alkyl).
6. The compound of Claim 1, wherein R^4 is an optionally substituted heteroaryl.
7. The compound of Claim 6, wherein the optionally substituted heteroaryl is an optionally substituted imidazole or an optionally substituted pyrazole.
8. The compound of Claim 1, wherein R^4 is an optionally substituted heteroaryl(C_{1-6} alkyl).
9. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted aryl.
10. The compound of Claim 9, wherein the optionally substituted aryl is an optionally substituted phenyl.
11. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted aryl(C_{1-6} alkyl).
12. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted heteroaryl.
13. The compound of any one of Claims 1-8, wherein R^5 is an optionally substituted heteroaryl(C_{1-6} alkyl).
14. The compound of Claim 1, wherein R^4 and R^5 are each a substituted phenyl substituted with one or more group selected from fluoro, chloro, iodo, C_{1-4} alkyl, C_{2-4} alkynyl, hydroxy, C_{1-4} alkoxy, an optionally substituted phenyl, cyano, $NC-(CH_2)-$, $H_2N-C(=O)-(CH_2)-$,


O-amido(CH₂)-, optionally substituted



and optionally substituted

15. The compound of Claim 1, wherein R⁴ and R⁵ are taken together to form an optionally substituted tricyclic heterocyclyl.

16. The compound of Claim 15, wherein the optionally substituted tricyclic heterocyclyl is an optionally substituted moiety selected from the group consisting of:



17. The compound of Claim 15 or 16, wherein the tricyclic heterocyclyl is substituted with one or more group selected from fluoro, chloro, iodo and C₁₋₄ alkyl.

18. The compound of any one of Claims 1-17, wherein R² is hydrogen.

19. The compound of any one of Claims 1-17, wherein R² is an optionally substituted C₁₋₆ alkyl.


20. The compound of Claim 19, wherein the optionally substituted C₁₋₆ alkyl is substituted with substituent selected from the group consisting of halogen, haloalkyl, hydroxy and alkoxy.

21. The compound of any one of Claims 1-17, wherein R² is an optionally substituted aryl(C₁₋₆ alkyl).
















22. The compound of any one of Claims 1-21, wherein R¹ is hydrogen.














23. The compound of any one of Claims 1-21, wherein R¹ is an unsubstituted C₁₋₄ alkyl.













24. The compound of any one of Claims 1-21, wherein R^1 is $-C(=O)Y^1$, $-C(=O)-O-Y^1$, $-(CH_2)-O-(C=O)-Y^1$, $-(CH_2)-O-(C=O)-O-Y^1$, $-(CHCH_3)-O-(C=O)-Y^1$ or $-(CHCH_3)-O-(C=O)-O-Y^1$.
25. The compound of Claim 24, R^1 is $-C(=O)Y^1$.
26. The compound of Claim 24, R^1 is $-C(=O)-O-Y^1$.
27. The compound of Claim 24, R^1 is $-(CH_2)-O-(C=O)-Y^1$.
28. The compound of Claim 24, R^1 is $-(CH_2)-O-(C=O)-O-Y^1$.
29. The compound of Claim 24, R^1 is $-(CHCH_3)-O-(C=O)-Y^1$.
30. The compound of Claim 24, R^1 is $-(CHCH_3)-O-(C=O)-O-Y^1$.
31. The compound of any one of Claims 24-30, Y^1 is an optionally substituted C_{1-6} alkyl.
32. The compound of any one of Claims 24-30, Y^1 is an optionally substituted C_{3-6} cycloalkyl.
33. The compound of any one of Claims 24-30, Y^1 is an optionally substituted aryl.
34. The compound of any one of Claims 24-30, Y^1 is an optionally substituted heteroaryl.
35. The compound of any one of Claims 24-30, Y^1 is an optionally substituted heterocyclyl.
36. The compound of any one of Claims 24-30, Y^1 is a mono-substituted amino group.
37. The compound of any one of Claims 24-30, Y^1 is a di-substituted amino group.
38. The compound of any one of Claims 24-30, Y^1 is $-C(R^7)NHR^8$.
39. The compound of Claim 38, wherein R^7 is hydrogen.
40. The compound of Claim 38, wherein R^7 is an optionally substituted C_{1-4} alkyl.
41. The compound of any one of Claims 38-40, wherein R^8 is hydrogen.
42. The compound of any one of Claims 38-40, wherein R^8 is an optionally substituted C_{1-4} alkyl.










44. The compound of any one of Claims 1-43, wherein R^6 is hydrogen.
45. The compound of any one of Claims 1-43, wherein R^6 is halogen or $-CN$.
46. The compound of any one of Claims 1-43, wherein R^6 is an optionally substituted C_{1-6} alkyl, an optionally substituted aryl or an optionally substituted heteroaryl.
47. The compound of any one of Claims 1-43, wherein R^6 is $-CH_2OH$, $-CH(Y^2)(OH)$ or $-C(O)Y^2$.
48. The compound of any one of Claims 1-47, wherein R^{3a} is hydrogen.
49. The compound of any one of Claims 1-47, wherein R^{3a} is an optionally substituted C_{1-4} alkyl.
50. The compound of any one of Claims 1-49, wherein R^{3b} is hydrogen.
51. The compound of any one of Claims 1-49, wherein R^{3b} is an optionally substituted C_{1-4} alkyl.
52. The compound of any one of Claims 1-51, wherein ----- is a single bond.
53. The compound of any one of Claims 1-51, wherein ----- is a double bond.













































and










, or a pharmaceutically acceptable

salt of the foregoing.


55. The compound of Claim 1, wherein the compound is selected from the group consisting of:






and , or a pharmaceutically acceptable salt of the foregoing.


56. The compound of Claim 1, wherein the compound is selected from the group consisting of:






pharmaceutically acceptable salt of the foregoing.


57. The compound of Claim 1, wherein the compound is selected from the group consisting of:




58. The compound of Claim 1, wherein the compound is




59. The compound of Claim 1, wherein the compound is




60. The compound of Claim 1, wherein the compound is




61. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.




62. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.




63. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.




64. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.




65. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.



66. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.




67. The compound of Claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.


68. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.


69. The compound of Claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.






70. The compound of Claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof.

71. The compound of Claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.


72. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.



73. The compound of Claim 1, wherein the compound is



and , or a pharmaceutically acceptable salt thereof.

74. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-73, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

75. Use of an effective amount of a compound of any one of Claims 1-73, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating an orthomyxovirus viral infection.

76. Use of an effective amount of a compound of any one of Claims 1-73, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting replication of an orthomyxovirus.

77. The use of Claim 75 or 76, further comprising the use of one or more agents.

78. Use of an effective amount of a compound of any one of Claims 1-73, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting the endonuclease activity of an influenza endonuclease.

79. The use of any one of Claims 75-76, wherein the orthomyxovirus is an influenza virus.

80. The use of Claim 77, wherein the orthomyxovirus is an influenza virus; and wherein the one or more agents is selected from the group consisting of a neuraminidase inhibitor, a M2 protein inhibitor, a polymerase inhibitor, a PB2 inhibitor, amantadine, rimantadine, zanamivir, oseltamivir, peramivir, laninamivir, laninamivir octanoate, favipiravir, fludase, ADS-8902, an immuno-modulator, beraprost, Neugene®, ribavirin, CAS Reg. No. 1422050-75-6, CAS Reg. No. 1259366-34-1 (VX-787), FluMist Quadrivalent® (MedImmune), Fluarix® Quadrivalent (GlaxoSmithKline), Fluzone® Quadrivalent (Sanofi Pasteur), Flucelvax® (Novartis) and FluBlok® (Protein Sciences).

81. The use of Claim 80, wherein the one or more agents is oseltamivir.

82. The use of any one of Claims 79-81, wherein the influenza virus is influenza A,

83. The use of any one of Claims 79-81, wherein the influenza virus is influenza B.

84. The use of any one of Claims 79-81, wherein the influenza virus is influenza C.

85. The use of any one of Claims 79-81, wherein the influenza virus is selected from the group consisting of H1N1, H3N2, H5N1 and H7N9.

86. The use of any one of Claims 79-85, wherein the compound of any one of Claims 1-73, or a pharmaceutically acceptable salt thereof, is effective against more than 1 subtype of influenza.